程国良;刘新灵;王维;程刚;
CHENG Guoliang;LIU Xinling;WANG Wei;CHENG Gang;School of Pharmacy,Shenyang Pharmaceutical University;National Chiral Pharmaceutical Engineering Technology Research Center;

• 1:沈阳药科大学药学院
• 2:国家手性制药工程技术研究中心

摘要(Abstract)：

目的通过Meta分析方法探讨替吉奥与卡培他滨对比治疗进展期胃癌的有效性和安全性。方法在Pubmed、Web of science、EBSCO、循证医学图书馆(Cochrane Library)、中国生物医学文献数据库(China Biology Medicine,CBM)、中国期刊全文数据库(China National Knowledge Infrastructure,CNKI)、维普数据库、万方数据库检索国内外研究替吉奥与卡培他滨单药或联合用药对比治疗进展期胃癌的随机对照临床试验,应用Open Meta analyst和Stata 12. 0软件对统计数据进行Meta分析。结果符合纳入和排除标准的文章共27篇,共1 945名患者。Meta分析结果显示,替吉奥组较卡培他滨组的客观缓解率更优(OR=1. 399,95%CI:1. 164-1. 681,P <0. 001),但亚组(替吉奥单药或联合奥沙利铂用药组)之间无统计学差异。两组总生存期和治疗失败时间均无统计学差异;但替吉奥组手足综合征和胃肠道不良反应发生率较低。结论替吉奥相较于卡培他滨在治疗进展期胃癌时的疗效和安全性有优势。
Objective To explore the efficacy and safety of S-1 and Capecitabine of treating advanced gastric cancer in clinical application with Meta analysis. Methods Systematically reviewing the clinical study about S-1 and Capecitabine for the treatment of advanced gastric cancer in the database of PubMed,Web of science,EBSCO,Cochrane Library,CNKI,CBM,VIP and Wanfang. Statistical analysis was completed in Open Meta analysis and Stata 12. 0. Results 1945 patients in 27 studies were included,which satisfied the included and excluded criteria. The results of Meta analysis showed that the response rate of S-1 was better than Capecitabine( OR = 1. 399,95% CI: 1. 164-1. 681,P < 0. 001),but there were statistical difference between subgroup analysis. And the overall survival and time to progression were both similar,but the side effects of HFS and gastrointestinal adverse events in the group of S-1 were less than the group of Capecitabine. Conclusion S-1 can be recommended as the dominant treatment for advanced gastric cancer for more efficacy and less side effects.

关键词(KeyWords)： 替吉奥;卡培他滨;胃癌;Meta分析
S-1;Capecitabine;advanced gastric cancer;Meta analysis

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 程国良;刘新灵;王维;程刚;
CHENG Guoliang;LIU Xinling;WANG Wei;CHENG Gang;School of Pharmacy,Shenyang Pharmaceutical University;National Chiral Pharmaceutical Engineering Technology Research Center;

DOI: 10.14066/j.cnki.cn21-1349/r.2018.11.011

参考文献(References)：

• [1] JEMAL A,BRAY F,CENTER MM. Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90.
• [2]郭仁宏. 2013 NCCN胃癌临床实践指南(2013. V2)要点介绍及解读[J].中国医学前沿杂志,2013,5(12):71-78.
• [3] WU B,YE M,CHEN H F,et al. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer:an economic evaluation in the Chinese context[J].Clinical Therapeutics,2012,34(2):468-479.
• [4] VAN C E,MOISEYENKO V M,TJULANDINn S.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer a report of the V325 study group[J]. J Clin Oncol,2006,24(31):4991-4997.
• [5] WELLS G A,SHEA B,O'CONNELL D,et al. The Newcastle Ottawa Scale(NOS)for assessing the quality of non-randomised studies in meta analyses. Available at http://www. ohri. ca/programs/clinical_epidemiology/oxford. asp,accessed 13th,January 2015.
• [6] LEE J L,KANG Y K,KANG H J,et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J]. British Journal of Cancer,2008,99(4),584-590.
• [7]章海燕,孙立柱.国产替吉奥胶囊单药一线治疗老年晚期胃癌临床研究[J].中国医学创新,2010,7(29):94-96.
• [8]邱国钦,许丽贞,林智才,等.替吉奥治疗老年进展期胃癌的临床观察[J].中国肿瘤临床与康复,2011,20(1):61-63.
• [9]孔永和,韩海林,李顺延.替吉奥胶囊治疗晚期胃癌的临床疗效分析[J].中国肿瘤临床与康复,2014,23(7):871-872.
• [10]王大鹏.替吉奥胶囊单药治疗晚期胃癌的临床观察[J].实用癌症杂志,2014,28(5):566-567.
• [11]刘庆春,王爱民,刘德传,等.替吉奥与卡培他滨治疗老年晚期胃癌临床疗效对比观察[J].人民军医,2016,11(11):1153-1155.
• [12]巴楠,吴敏,王丽娟,等.替吉奥或卡培他滨联合顺铂治疗晚期胃癌临床疗效研究[J].中国全科医学,2012,15(6):672-673,676.
• [13]闫泽,兆天欣,邢影,等.替吉奥联合顺铂治疗晚期胃癌临床疗效研究[J].现代生物医学进展,2012,12(27):5324-5326.
• [14]王月,蔡哲,成建,等.替吉奥联合奥沙利铂治疗老年进展期胃癌的疗效[J].中国老年学杂志,2011,31(9):1504-1505.
• [15]魏光敏.奥沙利铂联合卡培他滨或替吉奥治疗进展期胃癌的疗效比较[J].中国老年学杂志,2012,32(2):369-370.
• [16]KIMG M,JEUNG H C,RHA S Y,et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer[J]. European Journal of Cancer,2012,48(4):518-526.
• [17]殷蓓蓓,李岩,梁婧,等.替吉奥联合奥沙利铂治疗进展期胃癌56例临床观察[J].现代中西医结合杂志,2013,22(18):1971-1972.
• [18]李薇,王蕴慧.卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗进展期胃癌的临床价值对比研究[J].中国实用医药,2014,28(11):175-176.
• [19]何万谋.替吉奥胶囊联合注射用奥沙利铂治疗进展期胃癌临床疗效和安全性的分析[J].实用癌症杂志,2014,28(8):978-980.
• [20]谢彦良,任统伟.卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗进展期胃癌的对比分析[J].中国实用医药,2014,34(9):156-158.
• [21]杨武,喻永龙,朱西平,等.替吉奥和卡培他滨分别联合奥沙利铂化疗对晚期胃癌疗效观察[J].蚌埠医学院学报,2014,31(11):1512-1514.
• [22]童流妹,徐惠亮,蒋红良. SOX方案及XELOX方案一线治疗晚期胃癌的临床研究[J].实用肿瘤杂志,2015,30(1):56-59.
• [23]曹凤,王德林,刘承伟,等.替吉奥或卡培他滨联合奥沙利铂治疗晚期胃癌的疗效观察[J].中国医院用药评价与分析,2016,16(10):1311-1314.
• [24]刘广国,罗文娟.替吉奥联合奥沙利铂治疗进展期胃癌的临床疗效分析及安全性评价[J].北方药学,2016,13(5):42-43.
• [25]孙桢.奥沙利铂联合卡培他滨或替吉奥治疗进展期胃癌的效果分析[J].河南医学研究,2016,25(11):2039-2040.
• [26]胥敏.奥沙利铂联合替吉奥或卡培他滨方案用于胃癌术后疗效对比[J].中国药业,2016,25(1):103-105.
• [27]熊海林,刘洵祺,孙爱华,等.多西紫杉醇联合希罗达或替吉奥一线治疗晚期胃癌的临床观察[J].现代肿瘤医学,2013,21(3):581-584.
• [28]高彩霞.替吉奥胶囊与紫杉醇联用治疗进展期胃癌疗效观察[J].当代医学,2015,21(9):133-134.
• [29]徐向东,张龙,瞿凯泉.含替吉奥联合化疗方案在进展期胃癌治疗中的应用探讨[J].中外医疗,2016,35(14):152-153,156.
• [30]李娜,李勇,巩平,等.热疗联合替吉奥治疗老年晚期胃癌的临床疗效[J].世界华人消化杂志,2015,21(3):445-450.
• [31]谭亚琴,张文慧,张巧凤,等. DOX方案与DOS-1方案治疗进展期胃癌的临床对比研究[J].疾病监测与控制,2015,9(9):627-630.
• [32]周锋,黄万钟,颜雯,等.替吉奥联合伊立替康与卡培他滨联合伊立替康治疗晚期胃癌的比较研究[J].现代诊断与治疗,2015,26(9):1966-1967.
• [33]司倩,孟祥瑞,陈楠,等.替吉奥与卡培他滨在老年晚期胃癌患者中的疗效与安全性的Meta分析[J].药物评价研究,2014,37(3):210-214.
• [34]刘文婷,张瑞雪,闫涵,等.中国进展期胃癌患者治疗中替吉奥与卡培他滨的疗效和安全性的Meta分析[J].实用医学杂志,2014,30(13):2138-2142.
• [35]王璐,沈国栋,陈尹,等.替吉奥或卡培他滨联合奥沙利铂治疗亚洲人群胃癌随机对照研究的Meta分析[J].中华肿瘤防治杂志,2014,21(21):1731-1738.